Evidence map›Paper›PMID 36145306›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [

Pascale Plas, Lorenzo Limana, Denis Carré, Amath Thiongane, Olivier Raguin, Rosalba Mansi, Florence Meyer-Losic, Stéphane Lezmi

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Comparison of the tolerability ofEuropean journal of nuclear medicine and molecular imaging · 2024
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Pascale PlasIPSEN Innovation, 91940 Les Ulis, France.
Lorenzo LimanaIPSEN Innovation, 91940 Les Ulis, France.
Denis CarréIPSEN Innovation, 91940 Les Ulis, France.
Amath ThionganeIPSEN Innovation, 91940 Les Ulis, France.
Olivier RaguinOncodesign, 21000 Dijon, France.
Rosalba MansiDivision of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.ORCID 0000-0003-0342-8865
Florence Meyer-LosicIPSEN Innovation, 91940 Les Ulis, France.ORCID 0000-0003-0245-2855
Stéphane LezmiIPSEN Innovation, 91940 Les Ulis, France.ORCID 0000-0002-3412-4058
Ipsen (France) · FRUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limited experiments have compared the treatment effects of repetitive cycles of radiolabelled somatostatin (SST) analogues. In vitro and in vivo experiments were conducted in an AR42J cancer cell model, comparing the antagonist [

Indexed as

[177Lu]Lu-DOTA-TATE[177Lu]Lu-satoreotide tetraxetanAR42Jpeptide receptor radionuclide therapysomatostatin receptor subtype 2

Identifiers

PMID36145306
PMCPMC9506113
OpenAlexW4293714736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.